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DRUGS AND PROGRESSIVE RENAL FAILURE
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What have we learned from clinical trials on prevention? The
incidence of end-stage renal disease is increasing at an alarm-
ing rate. While diabetes is now the most common cause of re-
nal failure, hypertension commonly coexists, exacerbating renal
damage and the other vascular complications of diabetes. Clini-
cal trials have shown the benefits of intervention strategies that
target not only the retardation of renal disease, but also the pri-
mary prevention of the conditions known to cause renal dam-
age. These strategies include: lifestyle modification programs
to prevent diabetes and hypertension; aggressive treatment of
established hypertension; combination antihypertensive regi-
mens; and the use of angiotensin-converting-enzyme inhibitors
and angiotensin II receptor blockers for additional renoprotec-
tion beyond that of blood pressure control. In addition, albu-
minuria and proteinuria have emerged as powerful predictors
of progression of renal disease. The present paper reviews the
results of available clinical trials and meta-analyses on these
interventional strategies, and highlights the potential of albu-
minuria and proteinuria in predicting renal and cardiovascular
outcomes.
End-stage renal disease (ESRD) is a major interna-
tional health problem. With the incidence of ESRD in-
creasing over the last 20 years [1], it is predicted that
this problem will only escalate, highlighting the need
to focus on intervention strategies that prevent ESRD.
However, for such strategies to be accepted, we need
well-constructed randomized control trials, specifically
addressing the issue of prevention of renal disease.
Alarmingly, in a recent review of randomized control
trials (RCTs) over the last 35 years, it was found that
nephrology had the lowest number of published RCTs
when compared to 12 other major specialties of internal
medicine. Further, fewer than 2% of all nephrology cita-
tions were RCTs [2].
Diabetes is the most common cause of ESRD in the
United States, Europe, Japan, and Australia [1, 3, 4]. Hy-
pertension, which commonly coexists, exacerbates not
only renal damage but also the other vascular compli-
cations of diabetes. In one study, the presence of both
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diabetes and hypertension led to a 5- to 6-fold increase in
the risk of ESRD compared to hypertension alone [5]. In
a recent community-based, longitudinal cohort study of
2585 participants, both diabetes and hypertension were
associated with an increased odds ratio of developing
early kidney disease (OR 2.60 and 1.57, respectively) [6].
Both conditions play an integral role in the progression of
renal disease from microalbuminuria to proteinuria and
on to renal failure, and so lend themselves well to possi-
ble prevention and intervention strategies. Furthermore,
the presence of both conditions leads to a higher risk of
cardiovascular disease, which remains the main cause of
mortality in the ESRD population [1, 7, 8].
PREVENTION OF DISEASE
The first step in prevention of renal disease is primary
prevention of the diseases that lead to ESRD. Diabetes
is a worldwide phenomenon with prevalence expected to
increase substantially over time due to increasing obesity
and sedentary lifestyle [9]. Three recent major studies
show that diabetes can be delayed, or even prevented, by
lifestyle intervention strategies. The first was a 6-year Chi-
nese study involving 577 patients with impaired glucose
tolerance (IGT) randomized into either placebo or one
of 3 active treatment groups—diet, exercise, or both [10].
All intervention groups were associated with reduced in-
cidence of diabetes compared with controls −31% (P <
0.03), 46% (P < 0.0005), and 42% (P < 0.005), respec-
tively, but there was no significant difference between
the intervention groups. The Finnish Diabetes Preven-
tion study involving high-risk patients with IGT showed
a 58% reduction (P < 0.001) in the cumulative incidence
of diabetes in those randomized to lifestyle intervention
[11]. A larger study by the Diabetes Prevention Program
involving 3234 patients with IGT across a wide range of
ethnic backgrounds confirmed the finding [12]. Partici-
pants were randomized into one of placebo, metformin
(850 mg twice daily), or lifestyle modification program
arms. Both lifestyle change and metformin reduced the
incidence of diabetes; however, lifestyle intervention was
more effective with 58% versus 31% reduced incidence.
The magnitude of risk reduction in the intervention arm
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was seen across all ethnic groups, and all body mass index
(BMI) subgroups achieved significant risk reduction.
There is a large body of evidence to support the bene-
ficial effects of lifestyle modification in primary preven-
tion of hypertension [13–17]. Such modifications include
weight reduction, regular exercise, reduction in sodium
and alcohol intake, and a diet rich in fruit, vegetables,
and low-fat dairy products. Strategies aimed at achieving
these goals have been shown to reduce blood pressure
in hypertensive, normotensive, overweight, and normal
weight patients [18]. In one study, the mean net reduction
in systolic blood pressure (SBP) after lifestyle modifica-
tion and regulation of diet was 4.3 mm Hg (P < 0.001),
with greater than one third of patients with stage 1 hy-
pertension at baseline achieving optimal blood pressure
(<120/80) by 6 months [19]. In one study, these benefits
were sustained over a 4-year period [20]. Thus, by target-
ing primary prevention of diabetes and hypertension with
lifestyle intervention programs, there is the potential for
substantial reductions in the incidence of their associated
complications and comorbidities, including renal disease.
TREATMENT OF HYPERTENSION
Control of blood pressure is essential to prevent or
slow the progression of both diabetic and nondiabetic
renal disease. Studies have shown that control of blood
pressure can slow the decline in glomerular filtration rate
(GFR) [21–23] and reduce the degree of proteinuria [24],
in addition to reducing the risk of poor cardiovascular
outcomes, which are common in patients with renal dis-
ease [21, 25, 26].
A substudy of The United Kingdom Prospective Dia-
betes Study (UKPDS) examined the impact of tight blood
pressure control on microvascular and macrovascular
complications in type 2 diabetics [21]. Tight blood pres-
sure control, regardless of the agent used, was associated
with a 37% reduction in the development of microvas-
cular complications, including nephropathy, which was a
larger risk reduction than was seen with tight glycemic
control. By 6 years, there was a 29% reduction in the risk
of microalbuminuria (P < 0.009), and a nonsignificant re-
duction in the risk of proteinuria (P = 0.061) in the tight
group.
Two meta-analyses confirmed that the long-term ben-
eficial effects of antihypertensive therapies on protein-
uria and rate of decline in GFR are proportional to the
degree of blood pressure reduction [27, 28]. In multivari-
ate analysis, every 10 mm Hg reduction in mean arterial
blood pressure caused a relative improvement in GFR of
0.18 mL/min per month [28]. In addition, post-hoc anal-
ysis of blood pressure data from a recent trial using an-
giotensin II receptor blockers (ARBs) showed that each
10 mm Hg rise in systolic blood pressure was associated
with a 6.7% increased risk of ESRD [29]. The effect of
low blood pressure also seems proportional to the degree
of proteinuria [30, 31]. In the Modification of Diet in Re-
nal Disease (MDRD) study [23], 840 patients with renal
disease of variable cause were randomized into either
usual blood pressure group (mean arterial pressure 107–
113) or low blood pressure group (mean arterial pres-
sure 92–98). The improvement in mean GFR decline with
lowering of blood pressure was more significant in pa-
tients with >3 g/day proteinuria (10 vs. 6.5 mL/min/year)
compared to those with 1 to 3 g/day proteinuria (6 vs.
4 mL/min/year). These studies show that blood pressure
control slows the decline of renal function, and that this
effect is more apparent at higher levels of baseline pro-
teinuria.
DO INHIBITORS OF THE
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
OFFER GREATER RENOPROTECTION THAN
CONVENTIONAL THERAPY?
Angiotensin-converting enzyme inhibitors (ACEIs)
and angiotensin II receptor blockers (ARBs) have been
shown to have additional renoprotective effects beyond
that of blood pressure control [27, 28, 32–35]. Meta-
analyses have shown they lead to greater reduction in
proteinuria [33, 36, 37], preservation of GFR [27, 28, 32],
and reduction in risk of progression to ESRD [34, 35]
across a spectrum of renal dysfunction in both diabetic
and nondiabetic renal disease.
Many studies have shown the beneficial effects of
ACEIs in type 1 diabetic [38–40] and nondiabetic [34,
35, 41–43] renal disease, with the relative risk reduction
of development of ESRD ranging from 30% to 50%
[44]. For example, the Captopril study [45] found a re-
duction in the risk of doubling of baseline serum creati-
nine (SCr) of 48% in those receiving captopril, despite
similar blood pressure reduction [45]. The Ramipril Effi-
cacy In Nephropathy (REIN) study [46] involved 352 pa-
tients with chronic nondiabetic nephropathy with GFR
between 20 to 70 mmol/L, proteinuria >1 g/day, and a
diastolic blood pressure of less than 90 mm Hg. Patients
receiving ramipril had smaller declines in GFR (0.53 vs.
0.88 mL/min per month), 50% reduction in proteinuria at
1 year, and a statistically significant reduction in progres-
sion to ESRD (P = 0.02) [46]. In multivariate analysis,
these benefits were independent of baseline or follow-
up blood pressure levels. In addition, ACEIs have been
shown to have a greater impact on patients with higher
levels of baseline proteinuria and more severe renal im-
pairment [23, 41, 42].
By contrast, consistent evidence of renoprotection
from ACEIs in type 2 diabetic renal disease is lacking
[47–51]. A review by Brenner summarized the conflicting
data, with some studies showing a reduction in protein-
uria and stabilization of GFR with ACEI therapy, some
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studies showing only a reduction in proteinuria, and other
studies failing to show either benefit [52]. In the few stud-
ies that have included definitive renal outcomes in their
end points, ACEI therapy did not show prevention or
slowing of progression to ESRD [50, 53].
However, 3 recent trials have provided evidence of the
renoprotective effects of ARBs in type 2 diabetic renal
disease beyond that of blood pressure control alone [54–
56]. The Irbesartan in Hypertensive, Microalbuminuric,
Type 2 Diabetic Patients Trial (IRMA 2) examined the
effect of irbesartan in patients with microalbuminuria,
hypertension, and type 2 diabetic renal disease. In ad-
dition to the benefits of blood pressure reduction, there
was a 70% reduction in risk of progression from microal-
buminuria to frank proteinuria with irbesartan 300 mg
daily [56]. The other 2 trials have shown the benefits of
ARBs in already established diabetic nephropathy. The
Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT)
involved 1715 patients with urinary protein excretion of
>900 mg/day randomly assigned to irbesartan, amlodip-
ine, or placebo therapy. Relative risk reduction of reach-
ing the composite end point of doubling baseline SCr,
ESRD, or death was 20% with irbesartan compared to
placebo (P = 0.02) and 23% compared to amlodipine
(P = 0.006). The relative risk of doubling SCr was 33%
lower with irbesartan than with placebo (P = 0.003), and
37% lower than with amlodipine (P < 0.001) [55]. These
outcome benefits were not reduced, even after adjust-
ment for minor disparities in blood pressure control be-
tween the groups. Similar results were obtained in the
Reduction of Endpoints in NIDDM with the Angiotensin
II Antagonist Losartan (RENAAL) study, which in-
volved 1513 patients with diabetic nephropathy (urinary
protein >500 mg/day) randomized to receive losartan or
placebo therapy in addition to conventional antihyper-
tensive treatment. Losartan (50-100 mg) showed a rel-
ative risk reduction of 16% (P = 0.02) in reaching the
composite end point, 25% (P = 0.006) for doubling of
SCr, and 28% (P = 0.002) in developing ESRD [54]. Both
of these trials provide ‘landmark’ evidence that interrup-
tion of the RAAS with ARBs in type 2 diabetics with
nephropathy delays progression of renal disease, inde-
pendent of their effects on blood pressure control.
Whether ACEIs would show an equivalent benefit in
type 2 diabetic nephropathy remains unclear because no
trials have compared the effects of ACEIs with those
of ARBs on progression to ESRD. The Candesartan
and Lisinopril Microalbuminuria (CALM) study [57] did
compare the effects of lisinopril and candesartan on
blood pressure control and urinary albumin excretion in
type 2 diabetics. Both treatments significantly reduced
mean systolic blood pressure compared to controls—
candesartan 12.4% and lisinopril 15.7% (P < 0.001 for
both), and urine albumin to creatinine ratio compared
to controls—30% and 46%, respectively (P < 0.001 for
both), with no significant difference between them [57].
However, this trial was of short duration and did not ex-
tend to renal outcome end points.
At this point, it needs to be noted that, while there is ev-
idence that ACEIs may be superior to other antihyperten-
sives in reducing cardiovascular morbidity and mortality
[58–60], a recent prospective overview of 29 randomized
trials suggested it is the degree of blood pressure reduc-
tion, rather than the particular agent used, which has the
most impact on cardiovascular outcomes [61]. This may
also be the case for renal disease, but specific evidence to
support this is lacking.
IMPORTANCE OF COMBINATION THERAPY
In most clinical trials highlighting the importance of
blood pressure control in preventing the progression of
renal disease, multiple agents (average 2–4) have been
required to achieve target blood pressure goals [5, 21, 22,
24, 25, 43]. Good results have been shown with the combi-
nation of ACEIs or ARBs and calcium channel blockers
[62–64], while recent trials suggest that double blockade
of the RAAS provides not only better blood pressure
control but also additive renal benefits [57, 65, 66]. The
CALM Study showed better systolic blood pressure con-
trol and greater reduction in urinary albumin excretion
in type 2 diabetics with combination lisinopril and can-
dasartan than with either alone (50% vs. 39% vs. 24%,
respectively) [57]. In addition, a small study of 10 patients
with chronic glomerulonephritis showed greater protein-
uria reduction with combination therapy, which was inde-
pendent of blood pressure control or baseline creatinine
clearance [67].
The Combination Treatment of Angiotensin-II
Receptor Blocker and Angiotensin-Converting-
Enzyme Inhibitor in Non-Diabetic Renal Disease Trial
(COOPERATE) [68] is the only trial to date to examine
whether combination therapy with ACEIs and ARBs
is more effective in retarding progression to ESRD
than either agent alone. This trial involved 263 patients
with nondiabetic nephropathy randomly assigned to
losartan, trandolapril, or combination treatment groups.
The combination group had reduced protein excretion
by 75.6% (P = 0.01) compared to 42.1% and 44.3%
for losartan and trandolapril alone. This antiproteinuric
effect was achieved across all levels of baseline protein-
uria. Further, combination therapy resulted in a 60%
reduction in risk of reaching the primary end point of
doubling of baseline SCr or ESRD compared to either
losartan or trandolapril alone (HR 0.40, P = 0.016 and
HR 0.38, P = 0.018, respectively) [68]. The frequency of
adverse events did not differ significantly between the
groups, with hyperkalemia occurring more frequently
in the trandolapril group than the combination group.
This recent evidence suggests that dual blockade of the
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RAAS is safe, has the potential to be more efficacious in
slowing renal decline than either agent alone and, thus,
warrants serious consideration.
ALBUMINURIA/PROTEINURIA
When addressing prevention strategies, it is useful to
have a reliable marker of risk of disease progression that
acts not only as a stimulus for preventative measures but
also as a target for potential beneficial strategies. Albu-
minuria and proteinuria are emerging as such markers.
While albuminuria is the better marker for low levels of
proteinuria, both are reliable markers for levels above
1 g proteinuria/day. It has been recently determined on a
community basis that low level proteinuria contains only
20% albumin, and that at higher levels (urine protein:
creatinine ≥0.8 mg/mg) albumin accounts for 70% of the
protein excreted [69]. Further, albuminuria is present in
6.6% of the Australian population, and the majority of
cases are among those with hypertension or diabetes [70].
Proteinuria has consistently been shown to be the
strongest predictor of progression of renal disease in
diabetic- and nondiabetic-related disease [31, 53, 71, 72].
In a meta-analysis by Jafar, the relative risk of progression
was found to be 5.56 for each additional gram per day of
proteinuria [36]. A higher degree of baseline proteinuria
not only leads to a faster decline in GFR [24, 46, 53], but
also predicts likelihood of renal outcomes [41, 73]. In the
IDNT Study, the risk of kidney failure doubled with each
doubling of baseline proteinuria, while for each halving of
proteinuria between baseline and 1 year of treatment with
irbesartan, the risk of kidney failure was reduced by more
than half (HR 0.39) [74]. In the RENAAL Study, patients
with high baseline albuminuria (>3.0 g/g) had a 5.2-fold
increased risk of the combined renal end points and an
8.1-fold increased risk of progressing to ESRD compared
to those with a low level of albuminuria (<1.5 g/g) [71].
Further, percentage reduction was shown to be predictive
of renal outcome [41, 71], with one study showing a 36%
reduction in risk of reaching a combined end point for ev-
ery 50% reduction in proteinuria in the first 6 months [71].
Whether proteinuria is predictive of outcome because it
is a marker of degree of renal damage, or whether albu-
minuria is causative, as has been hypothesized [75], has
not yet been established.
In addition to the predictive role in outcomes, degree
of proteinuria is also predictive of response to treatment.
One meta-analysis reported the antiproteinuric effects
of ACEI treatment and lowering of blood pressure were
greater in those patients with higher baseline proteinuria
[36]. This was also seen in a large study of nondiabetic
renal disease, where the renoprotective effect of ramipril
was greater in those with proteinuria >1.5 g/24hr [46]. It
is not limited to only high levels of proteinuria. In the
Heart Outcomes Prevention Evaluation (HOPE) study,
which included both diabetic and nondiabetic patients
at high cardiovascular risk, those with microalbuminuria
at baseline had a 15- to 20-fold higher risk of develop-
ing overt nephropathy than those without [73]. It is not
only predictive for patients already with renal disease
or at high cardiovascular risk. A large, population-based
study in Japan involving 107,192 subjects found protein-
uria to be the most potent predictor of renal disease, with
a 14-fold increased relative risk of ESRD over 10 years
[76]. Furthermore, proteinuria has been found to be an
important predictor of cardiovascular outcomes [8, 77].
In a subgroup of the HOPE study of patients with re-
nal impairment, microalbuminuria was found to be an
independent predictor of the combined cardiovascular
outcome of death, myocardial infarction, or stroke [78].
Thus, proteinuria and albuminuria of varying levels have
been shown to be strong and consistent predictors of both
renal and cardiovascular outcomes.
CONCLUSION
Our current aging population, and increasing inci-
dence of obesity and diabetes are having a profound ef-
fect on the prevalence of ESRD, which in turn places
a significant burden on health services and resources.
The problem is predicted to escalate unless substantial
change is effected. Diabetes and hypertension are ma-
jor causes of ESRD. They share a complex relationship,
often coexisting and exacerbating the complications of
the other, including renal damage [5, 79]. Clinical tri-
als have shown the benefits of prevention strategies at
various stages of renal disease. Lifestyle modification
programs can prevent the development of diabetes and
hypertension. Aggressive control of blood pressure can
retard the progression of renal disease, with greater ben-
efit seen in those with higher degrees of proteinuria.
Agents that block the renin-angiotensin-aldosterone sys-
tem have been shown to provide additional renoprotec-
tion beyond that of blood pressure control to slow the
development of ESRD. Combination antihypertensive
therapy has generally been shown to be necessary, and
the combination of ACEIs and ARBs seems to confer
more renoprotection than either agent alone. Further,
albuminuria and proteinuria are powerful early indica-
tors of increased renal and cardiovascular risk and, thus,
provide excellent targets for future prevention strategies.
Raised awareness of the pivotal roles of diabetes and
hypertension, and the predictive capacity of albuminuria
and proteinuria, together with swift implementation of
focused preventative strategies, are our tools to atten-
uate and, ultimately, reverse the increasing incidence of
ESRD. Further randomized controlled trials assessing the
initial impact and sustained benefit of intervention strate-
gies would undoubtedly aid the process.
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